WPP Wins PR for 3 Pfizer Drugs

Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.

Pfizer’s decision last week to award $5-10 million in global public relations chores for three drugs to a team of WPP Group shops is the latest example of how PR reviews, paralleling other disciplines, are becoming holding-company affairs.

Teams from Interpublic Group, WPP Group and Omnicom Group —not individual agencies—battled for the assignment, which includes cholesterol drug Lipitor, hypertension drug Norvasc, and Caduet, a combination of Lipitor and Norvasc awaiting FDA approval.

“Before, we treated [the drugs] as separate brands,” said Michal Fishman, Pfizer director of U.S.



AW+

WORK SMARTER - LEARN, GROW AND BE INSPIRED.

Subscribe today!

To Read the Full Story Become an Adweek+ Subscriber

View Subscription Options

Already a member? Sign in